Published in:
Open Access
01-09-2009 | Letter
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
Authors:
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J. P. Hallé, I. Hramiak, P. Johnston, M. Davis
Published in:
Diabetologia
|
Issue 9/2009
Login to get access
Excerpt
To the Editor: We have reported a randomised, long-term safety study comparing the effects of using the insulin analogue glargine (A21Gly,B31Arg,B32Arg human insulin) versus human neutral protamine Hagedorn (NPH) insulin for 5 years in the management of type 2 diabetes [
1]. The study, in which 1017 patients were randomised and treated, was designed to assess ocular complications of diabetes: there was no excess of such effects with insulin glargine compared with NPH insulin treatment and there was a similar slow progression of diabetic retinopathy with both types of insulin. Because of recent concerns about postulated neoplastic effects of insulins [
2‐
5], we report here additional information from our study that bears on this question. …
